EDTA Chelation Therapy in the Treatment of Vascular Disease

Chappell, L. Terry; Janson, Marnie T

doi:10.1097/00005082-199604000-00008

Cited by 18 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EDTA might prevent iron to form complex with doxorubicin, which could prevent damaging induced by reactive oxygen species (Hasinoff, 2006). It is commonly used also to treat cardiovascular diseases (Chappell, Janson, 1996). Furthermore, EDTA could be important as an adjuvant for increasing the intratumoral efficacy of cisplatin (Cis) treatment (Duvillard et al, 2004;Pajak, Orzechowski, 2007).…”

Section: Introductionmentioning

confidence: 99%

Antitumor efficacy of EDTA co-treatment with cisplatin in tumor-bearing mice

El-Said

2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Ethylenediamine tetraacetic acid (EDTA) is used in various medical applications. The aim of this study is to investigate the antitumor efficacy of EDTA alone or with cisplatin (Cis). Fifty male albino mice were used to assess the median lethal dose (LD 50) of EDTA via intraperitoneal (i.p) injection. To determine the antitumor activity, fifty female albino mice were divided into five groups as the following; Group 1 (Gp1) was negative control; (Gp2-5) inoculated i.p with 2×10 6 Ehrlich Ascites Carcinoma (EAC) cells/mouse. After one day, Gp3, Gp4 and Gp5 injected with Cis (2 mg/kg), EDTA (25 mg/kg) and Cis (2 mg/kg)/EDTA (25 mg/kg) for six days, respectively. At day 14, all groups were sacrificed to assess the tumor profile, liver enzymes (alanine transaminases and aspartate transaminases), kidney function (urea and creatinine) and electrolytes (Na + , K + and Ca 2+). The results showed that the i.p LD 50 of EDTA was 250 mg/kg. Treatment with EDTA alone did not show any antitumor activity and did not interfere with the antitumor efficacy of Cis. Biochemical findings revealed that EDTA had mild toxicity on liver and kidneys functions. In summary, EDTA had no antitumor effect and did not alter the Cis efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

Antitumor efficacy of EDTA co-treatment with cisplatin in tumor-bearing mice

El-Said

2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Their observations are being investigated further in ongoing trials (TACT2) [71], suggesting chelation of lead and cadmium as a possible cause of the hypothesized therapeutic action [71,79]. Protocol discrepancies in the initial TACT study have been commented [80], and the researchers had no information on the vitamin K status of their participants. A JAMA editorial concluded that the findings of TACT should not be used as a justification for increased use of this controversial therapy [81].…”

Section: The Use Of Edta Chelation Therapy In the Context Of Vascular...mentioning

confidence: 99%

Vitamin K and Calcium Chelation in Vascular Health

Aaseth,

Alehagen,

Opstad

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The observation that the extent of artery calcification correlates with the degree of atherosclerosis was the background for the alternative treatment of cardiovascular disease with chelator ethylenediamine tetraacetate (EDTA). Recent studies have indicated that such chelation treatment has only marginal impact on the course of vascular disease. In contrast, endogenous calcium chelation with removal of calcium from the cardiovascular system paralleled by improved bone mineralization exerted, i.e., by matrix Gla protein (MGP) and osteocalcin, appears to significantly delay the development of cardiovascular diseases. After post-translational vitamin-K-dependent carboxylation of glutamic acid residues, MGP and other vitamin-K-dependent proteins (VKDPs) can chelate calcium through vicinal carboxyl groups. Dietary vitamin K is mainly provided in the form of phylloquinone from green leafy vegetables and as menaquinones from fermented foods. Here, we provide a review of clinical studies, addressing the role of vitamin K in cardiovascular diseases, and an overview of vitamin K kinetics and biological actions, including vitamin-K-dependent carboxylation and calcium chelation, as compared with the action of the exogenous (therapeutic) chelator EDTA. Consumption of vitamin-K-rich foods and/or use of vitamin K supplements appear to be a better preventive strategy than EDTA chelation for maintaining vascular health.

show abstract

“…Nissel [45] beschrieb einen 77ja È hrigen Patienten mit seit Jahren zunehmenden arteriosklerotischen Gefa È ssvera Èn-derungen, der u È ber 3 Wochen Chelatinfusionsbehandlungen erhielt und etwa 7 Stunden nach der letzten Infusion mit hochgradiger Hypokalza È mie unter den Zeichen eines ausgepra Ègten Hirno È dems in der Klinik trotz aller therapeutischen Bemu È hungen verstarb. In Ûbersichtsarbeiten wurden folgende Nebenwirkungen subsumiert: allergische Reaktionen, Hypokalza È mie mit konsekutiver Tetanie, Nephrotoxizita È t (Tubulusnekrosen bis Nierenversagen), lokale Thrombophlebitis, Hypotension, Hypoglyka Èmie, Schlaganfall, Magenbeschwerden , Herzrhythmussto È rungen, Atemstillstand [27,36,37,46]. Leichtgla Èubigkeit der Patienten fu È hrt zur Non-Compliance «Niemand ist so leichtgla Èubig wie jemand, der an einer Krankheit leidet» (W. H. Taft, amerikanischer Pra Èsident 1909±1913).…”

Section: Sanfte Medizin?unclassified

Über die laquo;Omnipotenz» der Chelattherapie

Meyer¹

1998

Complement Med Res

View full text Add to dashboard Cite

About the ‘Omnipotence’ of the Chelation Therapy In the eighties the ‘method of treatment proven in many thousands of cases over 20 years’ was transferred from the USA to Germany (enjoys a priori considerable faith) using very dubious promises. It was Clarke et al. who introduced this ‘therapy’ in 1955. The dubious promise was to maintain that the chelation therapy eliminates or alleviates symptoms in the case of the following illnesses: Alzheimer’s disease, senility, schizophrenia, rheumatoid arthritis, osteoarthritis, gout, renal calculus, apoplectic coma, gallstones, multiple sclerosis, osteoporosis, chronic fatigue syndrome, varicose veins, hypertension, failure of memory, scleroderma, Raynaud’s disease, digitalis intoxication, intermittent claudication, diabetic ulcer, disturbance of the blood supply, ulcer on the legs, snake poison, impotence, emotional difficulties, defective hearing, vision disorder. There is not the slightest proof of effectiveness for any of the listed indications. The burden of proof lies with the supplier. Even in the case of the relatively often examined peripheral atherosclerotic changes (claudicatio intermittens) there is no proof that EDTA has a greater effect than placebo. For coronary heart disease too there is no evidence for any usefulness of the chelation therapy beyond that of a placebo effect. Only controlled studies can help to improve the therapy in the sense of ‘Evidence-based medicine’. Retrospective investigations on thousands of patients cannot ‘prove’ anything, although this is maintained again and again.

show abstract

EDTA Chelation Therapy in the Treatment of Vascular Disease

Cited by 18 publications

References 0 publications

Antitumor efficacy of EDTA co-treatment with cisplatin in tumor-bearing mice

Antitumor efficacy of EDTA co-treatment with cisplatin in tumor-bearing mice

Vitamin K and Calcium Chelation in Vascular Health

Über die laquo;Omnipotenz» der Chelattherapie

Contact Info

Product

Resources

About